February 2001
From Noonan/Russo Communications
Pioneer in role and uses of SNPs in pharmaceutical development to present at the IBC pharmacogenomics, SNPs & genetics patenting conferencePRINCETON, N.J., February 12, 2001 -- Orchid BioSciences, Inc. (Nasdaq: ORCH) will present its leading single nucleotide polymorphism (SNP) analysis technology, SNP-IT�, at the IBC Pharmacogenomics, SNPs & Genetic Patenting Conference in San Diego on February 13, 2001. For more information on the conference, please visit http://www.ibc-lifesci.com/usc/2611 Who: Michael Boyce-Jacino, Ph.D., Chief Technology Officer and Vice President, R&D, Orchid BioSciences, Inc. Dr. Boyce-Jacino is among the pioneers in the field of SNPs. Over the last decade, Dr. Boyce-Jacino has developed leading technologies for SNP analysis and conducted pioneering research in human SNPs. It was Dr. Boyce-Jacino�s group that coined the term "single nucleotide polymorphisms, or SNPs" in the early 1990s. Where:IBC Pharmacogenomics, SNPs & Genetics Patenting Conference Sheraton San Diego Hotel and Marina San Diego, CA When: Tuesday, February 13, 2001 11:00 AM PST, 2:00 PM EST TV producers: Video B-roll of Orchid�s technology is also available.Background on Dr. Michael Boyce-Jacino
Dr. Boyce-Jacino has served as vice president of research and development of Orchid since 1998 and has served as chief technology officer since January 2001. From 1991 until it was acquired by Orchid in 1998, Dr. Boyce-Jacino served in a number of senior positions at Molecular Tool, where he was most recently president. Molecular Tool pioneered the first innovative technologies for SNP analysis in the early 1990s. Dr. Boyce-Jacino has more than 15 years of scientific experience in molecular genetics and biochemistry and holds numerous patents for his work in genotyping technologies. While at Molecular Tool, Dr. Boyce-Jacino led the development of proprietary technologies for high-volume, low-cost analysis of DNA sequence variations and conducted the company's pioneering research in human SNP analysis. Dr. Boyce-Jacino received his Bachelor of Science in Medical Microbiology from the University of Wisconsin Madison, and his Ph.D. in Microbiology from the University of Minnesota. About Orchid BioSciences, Inc.
Orchid BioSciences, Inc. (Nasdaq: ORCH) is a leading provider of products, services and technologies for single nucleotide polymorphism (SNP) scoring and genetic diversity analyses. Its proprietary SNP-IT� SNP analysis technology is the foundation for Orchid's SNPstream� instruments and SNPware� consumables that rapidly and cost effectively generate highly accurate SNP information. SNP-IT is adaptable to environments ranging from small-scale laboratories to large commercial facilities. Its versatility enables Orchid's Platform Propagation� strategy, in which Orchid partners with industry leaders to make SNP-IT enabled products available on a wide variety of instrument platforms. Orchid provides high throughput SNP scoring services to pharmaceutical, biotechnology and academic customers through its MegaSNPatron� facility, and DNA testing through its GeneScreen facilities, which conduct paternity, forensics, transplantation and pharmacogenetic testing. Through its Pharmaceutical Value Creation business, Orchid seeks to identify proprietary medical applications of SNPs. More information on Orchid can be found at www.orchid.com. For more information please contact:
Orchid BioSciences, Inc.
609-750-2200
Tracy Henrikson
Associate Director, Corporate Communications Noonan/Russo Communications, Inc.
212-696-4455
Ernie Knewitz, ext. 204, or
Matthew Scampoli, ext. 243
| |